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Urological Institute, Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USASeveral prospective randomized trials have not been able to
show a benefit with daily administration of phosphodies-
terase type 5 inhibitors for recovery of erectile function
following radical prostatectomy (RP) [1]. Consequently,
both basic and translational researchers are continuing to
search for effective strategies to preserve erectile function
following RP.
Despite the discovery of autonomic (sympathetic and
parasympathetic) innervation and neurovascular bundles
by Walsh and Donker in 1982 [2] and the advent of nerve-
sparing surgical techniques, erectile dysfunction remains a
common complication following RP. This is believed to be
caused by traction, crushing, and coagulation on or in
proximity to the neurovascular bundles, resulting in nerve
injury (neuropraxia) that triggers wallerian degeneration,
resulting in denervation of the corpora cavernosa and
erectile failure. Neurodegeneration is potentially reversible,
as the peripheral nervous system has an intrinsic neuror-
egenerative capacity in which the endogenous production
of neurotrophic factors is believed to be a key component in
the neuroprotective response to nerve injury [3]. This
concept has been confirmed in several preclinical studies in
which neuromodulatory or neurotrophic factor therapies
led to improved erectile function in rodents after cavernous
nerve injury (CNI) [4].
Several authors have suggested that sympathetic hyper-
innervation may play a role in the impairment of erectile
function following RP by potentially activating pathways
leading to apoptosis and hypercontractility of cavernosal
smooth muscle fibers such as the RhoA/Rho-associated
kinase (ROCK) pathway. Martinez-Salamanca et al showedDOI of original article: http://dx.doi.org/10.1016/j.eururo.2014.10.013.
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penes following RP and rat penes after experimental CNI
were overtly responsive to adrenergic stimulation, whereas
nitrinergic relaxation was impaired compared with corpo-
ral tissue without nerve injury [5,6]. Furthermore, Hsieh
et al have shown that, following injury to the cavernous
nerves, regenerated sympathetic fibers seem to outweigh
regenerated parasympathetic fibers [7]. It has further been
postulated that sympathetic dominance of innervation of
the corpora cavernosa may play a role in penile shortening,
which has been reported frequently by patients who have
undergone RP.
Nerve growth factor (NGF) was, historically, the first
neurotrophin to be discovered—due to its trophic action on
sensory and sympathetic neurons—in 1951 by Rita Levi-
Montalcini and Stanley Cohen, whowere awarded the Nobel
Prize for Physiology orMedicine in 1986 for their pioneering
work [8]. These researchers described a close relationship
between NGF and the sympathetic nervous system, as they
found that the injection of anti-NGF antibodies led to the
destruction of sympathetic ganglia in mammals, which they
referred to as immunosympathectomy. In the early 1960s it
was shown for the first time that inhibition of specific NGF
receptors could influence the survival of adistinct population
of autonomous neurons (ie, sympathetic) and thus could
hypothetically be used to influence the balance between
parasympathetic and sympathetic innervation.
NGF was the first neurotrophin shown to increase axonal
neurite outgrowth from the major pelvic ganglion (MPG)
cultured ex vivo, but it was unclear whether this neuror-
egenerative effect was different for individual neuronaln, Herestraat 49, 3000 Leuven, Belgium. Tel. +32 16 34 69 30;
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neurturin, was shown to preferentially stimulate outgrowth
in parasympathetic but not sympathetic pelvic neurons, as
these do not express neurturin’s growth factor receptor
GFRA2 [9]. The neurotrophic role of NGF on pelvic parasym-
pathetic neurons is currently less understood than it is for
sensory neurons and sympathetic neurons. Three months
afterunilateral cavernousnerve freezing,upregulationofNGF
protein expression in the penile tissue anddownregulation of
NGF gene expression occurs in the MPG of rodents [10]. This
led to the hypothesis that the penis, specifically, the penile
smooth muscle tissue, is a source of NGF production that is
transported retrogradely along the cavernous nerve to
influence, positively or negatively, neuromodulatory or
neuroprotective action on neurons in the MPG.
In the study by Lin and colleagues in this month’s issue of
European Urology, the authors administered a selective
monoclonal blocking antibody against neurotrophic tyrosine
kinase receptor type 1 (TrkA) to block NGF signaling in a rat
model of cavernous nerve injury [11]. The rationale for this
approachwas thatNGF/TrkA signaling regulates sympathetic
neuron growth cone formation, and blocking this interaction
could selectively inhibit either regeneration of sympathetic
innervation or aberrant sympathetic neuritogenesis to the
corpora cavernosa smoothmuscle. The authors showed that,
indeed, treated rats recovered their erectile function, and this
was paired with a restored balance between expression of
tyrosinehydroxylase (TH; amarker for sympatheticneurons)
and neuronal nitric oxide (nNOS; expressed in nonadrener-
gic/noncholinergic [NANC] parasympathetic fibers). Inter-
estingly, semiquantitative analysis of immunostained penile
and MPG sections showed increased presence of nNOS-
expressing fibers in the dorsal nerve and MPG after TrkA-
antibody treatment. The molecular mechanism responsible
for these changes remains to be determined.
Lin and colleagues hypothesize that blockage of NGF
binding to TrkAmayprovoke a positive shift in sensitivity for
neurotrophins, specifically promoting parasympathetic pro-
tection or regeneration (eg, neurturin) [11]. Although the
images of immunofluorescent staining of the dorsal nerve
and theMPG support this hypothesis, the effects on the ratio
of TH:nNOS in the western blot experiment (quantitative)
seem influenced by a TH decline, whereas nNOS levels are
relatively stable. The latter fits the paradigm that NGF
blockade results in a functional sympathectomy. Secondary
treatment effects of the TrkA antibody were prevention of
fibrosis andsmoothmuscle loss in thecorpora cavernosa.The
question remainswhether these secondary effects are due to
improved oxygenation of these tissues by activity of
regenerated NANC fibers or a direct inhibitory effect on
fibrotic pathways under sympathetic control, such as RhoA/
ROCK signaling.
We believe that Lin et al [11] have contributed to a recent
field of the use of monoclonal antibodies to modulate
endogenous neuroregeneration. Further research will haveto determine whether systemic administration of these
compounds will influence or stimulate growth of parasym-
pathetic fibers in prostate cancer patients that may have
microscopic disease and thus may effect prostate cancer
tumor growth and recurrence [12]. Furthermore, thequestion
inevitably arises of whether inhibiting an ubiquitously
present neurotrophic receptor, which is essential not only
for neuritogenesis of the cavernous nerves but also for
maintenance of neuronal cell health, may have detrimental
effects on sympathetic innervation throughout the body.
More specifically, blockage of NGF signaling in the lower
urinary tract may influence recovery of continence or
sphincter function (under sympathetic control), especially
in the setting of an already damaged bladder neck, such as is
the case after RP.
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